Lucid Group Elevates Rod MacKenzie to Board Chair to Fuel Global Growth and Innovation

Lucid Group Welcomes Rod MacKenzie as New Board Chair

In a strategic move aimed at accelerating its growth and innovation, Lucid Group has appointed Rod MacKenzie, CMG, PhD, as the new Chair of its Board of Directors. Formerly the Executive Vice President and Chief Development Officer at Pfizer, MacKenzie brings a wealth of experience in healthcare and a commitment to translating scientific advancements into real-world patient benefits.

This significant appointment will enable Lucid Group to further its mission of transforming the lives of patients by ensuring that innovative treatments do not simply sit on the shelf after reaching regulatory approval. Instead, the focus is on integrating these advancements into the healthcare marketplace effectively, thereby increasing their accessibility to those in need.

Rick Sannem, CEO of Lucid Group, emphasized the importance of MacKenzie's leadership, stating, "Dr. MacKenzie's career is defined by his dedication to patient outcomes and a deep understanding that breakthrough science only matters when translated into action." Indeed, his extensive 34-year tenure at Pfizer saw him lead initiatives that have had a lasting impact on public health, including overseeing the development of the Pfizer-BioNTech COVID-19 vaccine and the antiviral treatment Paxlovid.

In recognition of his outstanding contributions during the pandemic, MacKenzie was honored with the title Companion of the Order of St Michael and St George by Queen Elizabeth II in 2022. His insights into the pharmaceutical landscape are invaluable, particularly in understanding that effective patient outcomes require more than just scientific breakthroughs. He stated, "Even brilliant science can struggle to break through... innovative companies need strategic partners like Lucid that can deliver meaningful behavioural changes."

As Lucid enters this new chapter, MacKenzie acknowledges the importance of interdisciplinary collaboration in enhancing patient outcomes. This involves the application of real strategic discipline in communication strategies that bridge the gap between scientific innovation and practical implementation.

In addition to MacKenzie’s appointment, Lucid Group is launching groundbreaking tools from its US Medical Affairs division at the upcoming Medical Affairs Professional Society (MAPS) conference. The tools—Influence Amplifier™ and Impact Validator™—are designed to enhance advisory capabilities and expand peer-to-peer communication relevance. These tools will provide actionable insights to medical affairs teams, helping them understand where to focus their efforts for maximum impact.

The Influence Amplifier™ tool utilizes real-time behavioral insights to connect communication with behavior change. Meanwhile, the Impact Validator™ employs a five-step framework to pinpoint where efforts can drive meaningful change in clinical settings, thus ensuring optimized interventions for targeted audiences.

Both tools are built to support Lucid’s vision of Precision Engagement™, a continuous cycle that furthers scientific influence and improves patient outcomes. Lucid is also offering free, short sessions titled Impact Calibration™ for Medical Affairs teams, allowing them to assess their current influence and identify growth opportunities.

As Lucid Group advances its strategy under the seasoned leadership of Rod MacKenzie, it stands poised to remain a leading voice in healthcare communications, further bridging the gap between scientific discovery and real-world patient impact. This unique approach has the potential to shape the future of healthcare, ensuring that life-changing medicines find their rightful place in the world.

For more information about Lucid Group and its initiatives, visit www.wearelucidgroup.com or follow them on LinkedIn.

About Lucid Group

Lucid Group is a global leader in healthcare communications and commercialization, dedicated to transforming lives by navigating clients through complex scientific landscapes and ensuring they leave a lasting impact on the market. With a focus on scientific rigor combined with strategic creativity, Lucid aims to uncover the insights that drive stakeholder behavior and facilitate the effective introduction of innovative healthcare solutions.